<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00356161</url>
  </required_header>
  <id_info>
    <org_study_id>CVK-HAI 1</org_study_id>
    <nct_id>NCT00356161</nct_id>
  </id_info>
  <brief_title>HAI Via Interventionally Implanted Port Catheter Systems</brief_title>
  <official_title>Open One-Arm Therapy Optimizing Trial on Regional Chemotherapy of the Liver Through an Interventionally Implanted A.Hepatica Port System in Patients With Liver Metastases or Primary Liver Neoplasms.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <brief_summary>
    <textblock>
      Procedures to provide interventional implantation of a port catheter system into the hepatic
      artery and adjacent regional chemotherapy of the liver are optimized in the scope of an open,
      single-arm trial in patients with metastases and cancers confined to the liver. The primary
      objective is the improvement of indication, implantation procedure, and regional
      chemotherapy. Secondary objectives are port patency, comparison of complications with a
      historical collective of patients provided with a surgical hepatic arterial port device
      (colorectal cancer patients only), progression free and overall survival, efficacy of
      maintaining regional chemotherapy with 5-FU in combination with systemic treatment in
      patients with extrahepatic progression, quality of life.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inclusion criteria:

        -  histologically confirmed hepatic cancer without symptomatic extrahepatic manifestation.

        -  non-resectable disease or hepatic resection or ablation in between the past 8 weeks.

        -  measurable disease (at least before hepatic resection)

        -  Karnofsky performance status =&gt; 70%, or ECOG status 0-2

        -  &gt;18 years of age

        -  life expectancy &gt; 6 months

        -  compliance of the patient

        -  written informed consent

      Exclusion criteria:

        -  second neoplasia within the past 3 years, except for non-melanotic skin cancer,
           adequately treated Ca in situ of cervix uteri, or adequately resected second colorectal
           cancer (in patients with liver metastases of colorectal cancer)

        -  symptomatic extrahepatic disease, in particular disseminated bone metastases, brain
           metastases

        -  liver cirrhosis with portal hypertension, active hepatitis B or C, previous percutaneous
           radiotherapy of the liver

        -  active infection

        -  history of gastric or duodenal ulcer

        -  symptomatic or uncontrolled peripheral arterial occlusive disease, history of stenosis
           of the renal artery.

        -  history of dilatative cardiomyopathy, vitium of mitral or aortic valve, persisting
           foramen ovale, atrial fibrillation

        -  artificial heart valve or vascular

        -  history of diabetic microangiopathy

        -  uncontrolled hyperthyriodism

        -  other severe concomitant disease (heart failure &gt;NYHA 2°, respiratory failure, renal
           failure &gt;stage2, liver failure (TPZ &lt;50%).

        -  inherited or acquired immunodeficiency syndrome

        -  contraindication against 5-FU

        -  pregnancy and nursing, no contraception

        -  limited contractual capability.

      After enrollment, an a port catheter catheter system is interventionally implanted into the
      hepatic artery and the patient is scheduled for regional chemotherapy according one out of 8
      pre-defined chemotherapy schedules. All regimens are based on 5-fluorouracil and leucovorin,
      and optionally contain intraarterial mitomycin, oxaliplatin, or additional intravenous
      irinotecan.

      Patients are followed up and evaluated for primary and secondary endpoints. After the
      inclusion of 50 patients treated and follow up at our institution, the study population has
      been extended to 100 patients in 8/2004.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2002</start_date>
  <completion_date>April 2008</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of evaluation and intervention group</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Complication rate (device implantation)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of device and regional therapy</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>prospective evaluation of port duration</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>comparison of complication and port duration with an historical collective of patients provided with a surgically implanted hepatic arterial port catheter system (liver metastases of colorectal cancer)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free and overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>efficacy of maintaining regional therapy combined with systemic chemotherapy in patients with extrahepatic progression while on study</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
  </secondary_outcome>
  <enrollment>100</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Liver Neoplasms</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Gallbladder Cancer</condition>
  <condition>Bile Duct Cancer</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>interventionally implanted hepatic arterial port catheter</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        see above

        Exclusion Criteria:

        see above
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bert Hildebrandt, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Charté Centrum Tumormedizin, CVK, D-13344 Berlin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hanno Riess, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Charité Centrum Tumormedizin, CVK, D-13344 Berlin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jens Ricke, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Klinik für Radiologie und Nuklearmedizin, Universität Magdeburg, Leipziger Str. 44, D-39120 Magdeburg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roland Felix, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Klinik für Strahlenheilkunde, CVK, Charité Universitätsmedizin Berlin, D-13344 Berlin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Neuhaus, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Charité Centrum Chirurgische Medizin, CVK, D-13344 Berlin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bert Hildebrandt, MD</last_name>
    <phone>++49 30 450 553636</phone>
    <email>bert.hildebrandt@charite.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hanno Riess, MD, PhD</last_name>
    <phone>++49 30 450 553112</phone>
    <email>hanno.riess@charite.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Charité Centrum Tumormedizin, Medizinische Klinik für Hämatologie und Onkologie, CVK</name>
      <address>
        <city>Berlin</city>
        <zip>13344</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bert Hildebrandt, MD</last_name>
      <phone>++49 30 450 553 636</phone>
      <email>bert.hildebrandt@charite.de</email>
    </contact>
    <investigator>
      <last_name>Annett Nicolaou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik für Radiologie und Nuklearmedizin, Otto-von-Guericke Universität Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maciej Pech, MD</last_name>
      <phone>+49 391 67-13030</phone>
      <email>radiologie@uni-magdeburg.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Ricke J, Hildebrandt B, Miersch A, Nicolaou A, Warschewske G, Teichgräber U, Lopez Hänninen E, Riess H, Felix R. Hepatic arterial port systems for treatment of liver metastases: factors affecting patency and adverse events. J Vasc Interv Radiol. 2004 Aug;15(8):825-33.</citation>
    <PMID>15297586</PMID>
  </reference>
  <verification_date>July 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2006</study_first_submitted>
  <study_first_submitted_qc>July 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2006</study_first_posted>
  <last_update_submitted>July 24, 2006</last_update_submitted>
  <last_update_submitted_qc>July 24, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2006</last_update_posted>
  <keyword>colorectal neoplasms</keyword>
  <keyword>hepatocellular carcinoma</keyword>
  <keyword>gallbladder cancer</keyword>
  <keyword>bile duct cancer</keyword>
  <keyword>hepatic arterial infusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Gallbladder Neoplasms</mesh_term>
    <mesh_term>Bile Duct Neoplasms</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

